|View printer-friendly version|
|Array BioPharma Accelerates Drug Discovery With State-of-the-Art Electronic Information System|
|BOULDER, Colo., Aug 6, 2001 /PRNewswire/ --|
- Array First in Industry to Integrate Use Throughout Its Discovery Organization -Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement with CambridgeSoft to develop a customized software solution for its expanding chemoinformatics needs. The electronic system will help Array's scientists accelerate their experimental drug design by making real-time and historical data available at the touch of a button.
"The power of this system is that the collective knowledge of each scientist at Array is accessible electronically, creating a more productive research environment," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "The software consolidates our existing electronic notebook with compound registry, analytical data and biological results into one system, making all information bench top accessible for each and every scientist."
Array's scientists generate many new experiments and processes every day. Many of the design processes used in the company's lead generation libraries and lead optimization strategies are novel. This information is often highly valuable to the company's chemists working on other projects. The benefits of the new electronic interface include an unparalleled opportunity to share knowledge across the organization, an enhanced ability to select and synthesize compounds as well as an accelerated capability to make high quality decisions.
"We are excited about the opportunity to collaborate with Array to help fully integrate their drug design data in an electronic format using as a base, the combination of ChemDraw, ChemOffice, E-Notebook and CambridgeSoft's web based solutions," said Michael G. Tomasic, Chairman and Chief Executive Officer, CambridgeSoft. "Array's chemistry organization has set the bar in the drug discovery industry by being the first to fully use this state-of-the-art chemoinformatics technology."
Array and CambridgeSoft will work together to customize Array's electronic information system over the next year. Serving as a showcase site, Array welcomes the opportunity to provide tours of its new system.
About Array BioPharma Inc.
Array BioPharma is a drug discovery company creating new drugs through innovations in chemistry and structural biology. Array's world-class scientific team integrates chemistry and structural biology with an information-based technology platform to create higher quality drug candidates. Array provides drug discovery expertise to collaborators and for its own proprietary research.
For more information on Array BioPharma, please visit the company's web site at www.arraybiopharma.com.
CambridgeSoft develops and markets life science enterprise solutions for biotechnology, pharmaceutical, and chemical industrial and academic research organizations. Software products include desktop to enterprise versions of ChemOffice, including ChemDraw, with knowledge management, research and discovery, and e-commerce applications. Web sites include ChemFinder.Com and ChemNews.Com for indexed database content and news, and ChemStore.Com for e-commerce. For information about CambridgeSoft products, services, and resellers worldwide, visit http://www.cambridgesoft.com, or call 800 315-7300 or 617 588-9100.
ChemOffice, ChemDraw, ChemFinder.Com, and ChemStore.Com are trademarks of CambridgeSoft.
Array BioPharma Safe Harbor Statement
This press release contains projections and other forward-looking statements that involve significant risks and uncertainties. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with third parties on their drug discovery activities and our ability to attract and retain experienced scientists and management as well as the risk factors contained in our reports filed with the Securities and Exchange Commission, including our final prospectus as filed on November 17, 2000. We are providing this information as of August 6, 2001. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X16354121SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, email@example.com